Background. Treatment of malaria has been compromised by the emergence of drug-resistant parasites. Consequently, novel agents are urgently needed from different sources including from medicinal plants. Thus, the current study aimed at evaluating the antimalarial activity of crude extract and solvent fractions of the leaves of Bersama abyssinica (B. abyssinica) against Plasmodium berghei infection in Swiss Albino mice. Method. A 4-day suppressive test was employed to evaluate the antimalarial effect of crude extract and solvent fractions against early infection. The curative and prophylactic effects of crude extract and fraction with the highest chemosuppression were further tested by Rane’s test and residual infection procedure. Parasitemia, survival time, packed cell volume (PCV), body weight, and rectal temperature of mice were used as evaluation parameters. Windows SPSS version 20 was used to analyze the data and analysis of variance (ANOVA) followed by Tukey’s post hoc test was used to compare data between groups. Results. The crude extract and aqueous fraction significantly (P<0.05 to 0.001) suppressed parasitemia followed by protection of PCV reduction resulting in prolonging the survival time but failed to protect body weight and rectal temperature reduction in all tested models. The ethyl acetate and chloroform fractions also showed significant chemosuppression and PCV protection in the 4-day suppressive test. The crude extract exhibited a chemosuppression of 49.51%, 57.94%, and 44.11% while the aqueous fraction showed suppression of 47.69%, 51.62%, and 37.07% in 4-day suppressive, curative, and prophylactic tests, respectively, at 400 mg/kg. Conclusion. The crude extract and fractions showed fairly moderate antimalarial activity, and the finding supports the traditional claims and previous in vitro studies. Thus, this may call for further studies to isolate chemical entities for additional safety and efficacy tests.
Background Serum lipid profile abnormalities are major predictors for coronary artery diseases. The relationship between demographic factors and dyslipidemia in Ethiopia is not completely explored. Thus, this study aimed to assess the prevalence and predictors of dyslipidemia among hypertensive patients in Lumame Primary Hospital. Methods A cross-sectional study was conducted from June to August 30, 2020, on the hypertensive patients in Lumame Primary Hospital. All adult hypertensive patients who visited the adult hypertensive care services during the study period were included. Interview-guided self-administered questionnaire and a chart review were used for data collection. Statistical Package for the Social Sciences (SPSS) software version 24.0 was used for data analysis. Results Out of 372 hypertensive patients, 190(51.1%) were females and the mean age of the study participants was 43.56 years (SD ± 4.31). The overall prevalence of dyslipidemia in this study was 48.4%. Besides the overall prevalence, the prevalence of TC, TG, LDL-c, and HDL-c was 73(19.6%), 91(24.5%), 60(16.1%), and 115(30.9%), respectively. Females were at higher risk for having high levels of TC (AOR = 2.31, 95% CI = 1.54–3.13), TG (AOR = 1.70, 95% CI = 1.34–3.79), LDL-c (AOR = 2.15, 95% CI = 1.56–2.86), and HDL-c (AOR = 2.67, 95% CI = 1.44–5.67) than males. Respondents who were from urban were at higher risk for having high levels of TC (AOR = 1.98, 95% CI = 1.04–6.83), TG (AOR = 1.78, 95% CI = 1.09–2.86), LDL-c (AOR = 3.01, 95% CI = 1.45–7.43), and HDL-c (AOR = 2.01, 95% CI = 1.94–4.55) than respondents who were from rural. Similarly, obese respondents were at higher risk for having high levels of TC (AOR = 2.03, 95% CI = 1.64–2.00), TG (AOR = 3.78, 95% CI = 1.06–6.42), LDL-c (AOR = 1.92, 95% CI = 1.66–2.12), and HDL-c (AOR = 4.23, 95% CI = 2.84–4.32) than to respondents who were underweight. Conclusion The prevalence of dyslipidemia among hypertensive patients was high. Independent variables such as age, gender, residence, family history of HTN, smoking, alcohol drinking, fruit diet habits, physical activity, DM, and BMI were significant determinants of dyslipidemia.
Introduction Since fever is a complicated physiological reaction to an infection or aseptic stimulus, finding safer solutions that are more potent and derived from plants is essential to resolving this issue. Bersama abyssinica (Melianthaceae) is traditionally used to treat fever, though this has yet to be proven scientifically. Objective The present study aimed to assess the antipyretic potential of leaf extract and solvent fractions of B. abyssinica . Methods The antipyretic activities of crude extract and solvent fractions of B. abyssinica leaves were evaluated using a yeast-induced pyrexia model at three different dose ranges (100mg/kg, 200mg/kg, and 400mg/kg) methanol extract as well as chloroform, ethyl acetate, and aqueous fractions to mice showing an increase in temperature of ≥0.5 °C. The rectal temperature of each mouse was recorded using a digital thermometer. To analyze the data, SPSS version 20 and one-way ANOVA followed by Tukey’s HSD post hoc test to compare results between groups were utilized. Results The crude extract demonstrated significant antipyretic potential (P<0.05 by 100 mg/kg and 200 mg/kg as well as P<0.01 by 400 mg/kg), with a maximum of 95.06% reduction in rectal temperature at 400 mg/kg, comparable to 98.37% at 2.5 hours by the standard drug. Similarly, all doses of the aqueous fraction, as well as 200 mg/kg and 400 mg/kg doses of the ethyl acetate fractions, resulted in a significant (P<0.05) reduction in rectal temperature when compared to the corresponding value of the negative control group. Conclusion Extracts of B. abyssinica leaves were found to have a significant antipyretic effect. Thus, the use of the plant for pyrexia in traditional settings has scientific ground.
Background Irrational use of drugs has been one of the major problems around the globe. However, the degree of the problem is higher in developing countries like Ethiopia. The WHO has developed several indicators to evaluate the practices of drug use. This study aimed to assess the overall drug use practices using standard WHO indicators in Lumame Primary Hospital. Methods Hospital-based retrospective cross-sectional study was employed to investigate the overall drug use practices at the hospital. Six hundred prescriptions were selected from a total of 19,242 prescriptions by systematic sampling technique over one year from July 1, 2019, to June 30, 2020, in a retrospective review. For the patient care study, 100 patients were selected for collecting the required information. Facility indicators were assessed by checking the availability of STG/formularies and essential drugs. The results were interpreted according to the standard values of WHO. Results All 600 sampled prescriptions were 100% standard. Weight, dosage form, and quantity were written in 1.5–13.3% of the prescriptions. Patient address was recorded in 51%, while qualification of prescriber and dispenser were recorded in 71.5% and 56% of the cases, respectively, but all other information were complete in 88.5–100% of the prescriptions. The mean number of drugs per encounter, generic prescribing, prescribing from essential drug list, encounters with antibiotics and injectable drugs were 2.3, 97.9%, 99.8%, 48.8%, and 11.2%, respectively. The average dispensing time was found to be 171.9 seconds. Percentage of actually dispensed drugs, adequacy of labeling, patient knowledge, and patient satisfaction were 95.3%, 22.6%, 83%, and 88%, respectively. About 92% of tracer drugs and all reading materials, except national drug list and facility-level drug formulary, were available in the study period. Conclusion Generally, appreciable results were obtained for most of the indicators but improvement in antibiotic prescribing, polypharmacy and labeling practice is recommended.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.